TAP Consulting’s Allena Pharmaceuticals ALNA Stock Holding History

TAP Consulting’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30	Closed	–	–	578
2021 Q4	$0	Buy	+30	New	+$23	﹤0.01%	587

Other funds holding ALNA

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TAP Consulting's ALNA Position: Q1 2022 in Review

TAP Consulting sold out of Allena Pharmaceuticals (ALNA) in Q1 2022, closing a stake of 30 shares.

TAP Consulting first reported a position in ALNA in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 28 funds tracked by Wall St. Rank hold ALNA as of Q1 2022.

TAP Consulting reported no remaining Allena Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
TAP Consulting sold 30 Allena Pharmaceuticals shares in Q1 2022.
TAP Consulting first reported a position in Allena Pharmaceuticals in Q4 2021 and held it in 1 quarter.
TAP Consulting's Allena Pharmaceuticals position peaked at $0 in Q4 2021.
28 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.